Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $48.22.

Several brokerages recently commented on TWST. The Goldman Sachs Group lifted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, July 9th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research report on Monday, August 5th. TD Cowen raised their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, June 13th. Finally, Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 5th.

Twist Bioscience Trading Up 1.2 %

NASDAQ:TWST traded up $0.47 during mid-day trading on Thursday, reaching $40.02. The company's stock had a trading volume of 681,212 shares, compared to its average volume of 1,012,583. The stock has a market cap of $2.33 billion, a P/E ratio of -11.91 and a beta of 1.76. The firm's fifty day moving average price is $48.47 and its two-hundred day moving average price is $42.64. Twist Bioscience has a 12-month low of $14.42 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same quarter last year, the company earned ($1.01) EPS. The firm's revenue for the quarter was up 27.7% on a year-over-year basis. Analysts predict that Twist Bioscience will post -3.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Paula Green sold 1,137 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the transaction, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Paula Green sold 1,137 shares of the company's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the sale, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $205,200.27. Following the completion of the transaction, the chief executive officer now owns 499,593 shares of the company's stock, valued at approximately $19,948,748.49. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,483 shares of company stock worth $781,448. Corporate insiders own 3.92% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TWST. Victory Capital Management Inc. bought a new position in Twist Bioscience in the 4th quarter valued at $274,000. Los Angeles Capital Management LLC purchased a new position in Twist Bioscience in the 4th quarter worth about $321,000. National Bank of Canada FI lifted its holdings in Twist Bioscience by 264,666.7% during the 4th quarter. National Bank of Canada FI now owns 79,430 shares of the company's stock valued at $2,751,000 after buying an additional 79,400 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Twist Bioscience by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company's stock valued at $16,522,000 after buying an additional 5,728 shares during the period. Finally, EdgeRock Capital LLC purchased a new stake in Twist Bioscience in the 4th quarter valued at about $30,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.